• 1
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471478.
  • 2
    Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:40704076.
  • 3
    Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327237.
  • 4
    Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757766.
  • 5
    O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:35973605.
  • 6
    Pfizer Inc. Data on file. 2008.
  • 7
    Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581611.
  • 8
    Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 2008;14:31243131.
  • 9
    Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:13291338.
  • 10
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.
  • 11
    Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:20112019.
  • 12
    Langenberg M, van Herpen CM, de Bono JS, et al. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor; a randomized phase II study of cediranib [abstract]. J Clin Oncol 2008;26.
  • 13
    Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9:117123.
  • 14
    Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186193.
  • 15
    Ewer MS, Lenihan DJ, Khakoo AY. Sunitinib-related cardiotoxicity: An interdisciplinary issue. Nat Clin Pract Cardiovasc Med 2008;5:364365.
  • 16
    Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006;367:168176.
  • 17
    Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754762.
  • 18
    Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003;139:901906.
  • 19
    Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease?Kidney Int Suppl 1992;36:S33S37.
  • 20
    Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:25002508.
  • 21
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.
  • 22
    Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol 2006;24:e48.
  • 23
    Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.
  • 24
    Skrzypiec-Spring M, Grotthus B, Szelag A, Schulz R. Isolated heart perfusion according to Langendorff—still viable in the new millennium. J Pharmacol Toxicol Methods 2007;55:113126.
  • 25
    Blasi E, Steidl J, Patyna S, et al. Modification of sunitinib malate (SU11248) blood pressure changes in rats [abstract]. Proceedings of AACR Annual Meeting, Los Angeles , CA , USA , 2007.
  • 26
    Patyna S, Heward JK, Evering W. Non-clinical safety evaluation of sunitinib, a novel multitargeted tyrosine kinase inhibitor [abstract]. Presented at the 25th Annual Meeting of the Society of Toxicological Pathology, Vancouver , BC , Canada , 2006.
  • 27
    Robert F, Sandler A, Schiller JH, et al. Sunitinib in combination with doxataxcel in patients with advanced solid tumors: A phase I dose-escalation study. Cancer Chemother Pharmacol 2010;66:669680.
  • 28
    DePrimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:111.
  • 29
    Haznedar JO, Patyna S, Bello CL, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multi-targeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009;64:691706.
  • 30
    Patyna S, Arrigoni C, Terron A, et al. Nonclinical safety evaluation of sunitinib: A potent inhibitor of VEGF, PDGF, KIT, FLT3 and RET receptors. Toxicologic Pathol 2008;36:905916.
  • 31
    Pfizer Inc. SUTENT, Summary of product characteristics. August 2008.
  • 32
    Kappers M, Van Esch J, Sluiter W, Sleijfer S, Danser AH, Van Den Meiracker A. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. 2010;56:675681.
  • 33
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:23352342.
  • 34
    Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:37063712.
  • 35
    Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560H576.
  • 36
    Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927934.
  • 37
    Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O’Dwyer PJ. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 2006;24:13631369.
  • 38
    Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 2008;106:153161.